Treg Therapies in Autoimmune Diseases

Discover trends & insights into the evolving Treg Therapy development landscape for Autoimmune Diseases, including Treg Therapy drug status, disease breakdown, top targets, and recent commercial deals.

Treg Therapies in Autoimmune Diseases Report

Recent advancements in Cell Therapy technologies have shown promise in the treatment of autoimmune diseases. Specifically non-engineered Regulated T cell (Treg) therapies have increased in popularity, due to their broad immune suppression, lower off-target risk, and manufacturing scalability.

The report offers insight into:

  • Drug Status: 59% of Treg therapies are at the preclinical stage, reflecting strong early-phase activity
  • Disease Breakdown: Graft-versus-host disease the most studies Indication
  • Top Targets: IL-2 and HLA-A2 most common, for the prevention of transplant rejection
  • Deals: $7.31B in deal value over the last decade, including a $2.09B collaboration between AstraZeneca and Quell Therapeutics
Treg Therapies in Autoimmune Diseases Website Image

You May Also Be Interested In…

Learn More About Autoimmune

What is Beacon Autoimmune?
  • The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
  • Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
  • Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
  • Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
Learn More About Beacon Autoimmune Request Demo

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration

Menu
Search Icon
Close Icon
Search